ArticleJournal of materials science. Materials in medicine2026
Synergistic antioxidant and anti-inflammatory scaffold based on ascorbic acid-enriched hydroxyapatite-PEG-ZnO composite from natural bone waste.
Article in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hydroxyapatite (HAp) derived from bovine bone waste was used to develop a bioactive composite scaffold incorporating polyethylene glycol (PEG), ZnO nanoparticles, and ascorbic acid (AA). This study aimed to fabricate a PEG-based HAp composite enriched with ZnO and AA and to evaluate the influence of these additives on the structural characteristics and biological performance of the scaffold. The resulting HAp-PEG-ZnO-AA composite was designed to provide a sustained release of Zn²⁺ ions while leveraging the antioxidant functionality of AA to enhance biological activity. X-ray diffraction (XRD) analysis indicated that PEG incorporation altered the crystallinity and grain size of HAp, while high-resolution transmission electron microscopy (HRTEM) and X-ray photoelectron spectroscopy (XPS) confirmed the successful integration of ZnO nanoparticles and AA within the HAp matrix. The composite exhibited enhanced antioxidant and anti-inflammatory activity compared to the HAp-PEG-ZnO scaffold without AA, whereas antibacterial performance was primarily attributed to the ZnO component. In vitro cytotoxicity assays using RAW 264.7 macrophage cells demonstrated that the composite was biocompatible at lower concentrations (cell viability > 90% at 6.25 µg mL⁻¹), while higher concentrations resulted in a marked reduction in viability accompanied by observable morphological changes. Overall, these findings suggest that AA incorporation synergistically improves the antioxidant and anti-inflammatory properties of the HAp-PEG-ZnO scaffold without compromising its antimicrobial activity or its biocompatibility at low dosages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.